Series C Investor Presentation

Second Quarter 2024

geneoscopy
Transforming Gastrointestinal Health


Geneoscopy's mission is to
empower patients and providers to
transform gastrointestinal (GI) health
through innovative diagnostic tests that
prevent, detect and monitor disease
©2024 GENEOSCOPY, INC.

Our novel technology platform will transform GI health

Innovative Platform	Novel **stool-derived eukaryotic RNA technology** protected by a robust intellectual property portfolio
$18B CRC screening opportunity	Technologically validated, clinically differentiated, and de-risked CRC screening assay with **FDA approval and CMS coverage expected in 1H2024**
Near-term commercial launch	**Partnering with Labcorp**, the largest laboratory provider, will provide the infrastructure, reach, and access for a scalable launch
Diversified pipeline	Comprehensive **diagnostic platform for IBD** disease management developed in partnership with biopharma
Capital efficient growth strategy	**Cash flow breakeven** anticipated within three years of commercial launch

Gastrointestinal diseases affect

1 in **4**

Americans

Source: NIH



Geneoscopy's technology platform is built for GI health

Stool
SOURCE OF GI BIOMARKERS

+

RNA
PROVIDING UNIQUE INSIGHTS



- Phenotypic
- Quantitative and measurable
- Real-time and dynamic

GENOSCOPY COMPETITIVE ADVANTAGE

IP Protection and Trade Secrets
for the testing of stool-derived eukaryotic RNA[1]

1 Geneoscopy granted patents include U.S. Patent No. 11,479,820, U.S. Patent No. 11,479,824, Japanese Patent No. 7109462, Australian Patent No. 2017348369, and Chinese Patent No. ZL201780080634.4

5 | PROPRIETARY AND CONFIDENTIAL ©2024 GENEOSCOPY, INC.


Our RNA approach provides a universal signal for disease detection
DNA
Storage
1,000s of DNA variants can induce premalignant or malignant transformation
RNA
Expression
Universal RNA signatures provide comprehensive detection of most DNA modifications
Protein
Application
Different proteins are generated based on RNA modifications to perform cell functions
6 | PROPRIETARY AND CONFIDENTIAL

Opportunity to offer solutions for numerous unmet medical needs

Unmet Medical Needs in GI	Testing Applications
Colorectal Cancer	Diagnosis
Inflammatory Bowel Disease	Screening
Lynch Syndrome / FAP	Surveillance
Celiac Disease	Treatment
Irritable Bowel Syndrome	Recurrence
	Drug Discovery

Deploying our first commercial test in CRC screening market

110M
Average risk individuals age 45-85

$18B
CRC screening market

- Noninvasive stool-based tests are seeing rapid adoption
- 44M average risk individuals remain unscreened
- One large player in at-home stool testing, making this segment primed for a fast follower

Sources: U.S. Census data, Gerieoscopy estimates (includes US markets only)

Colorectal cancer is the 2nd deadliest cancer worldwide

1 in 24
Diagnosed with CRC

63%
Diagnosed with late stage

>50K
Annual deaths in US

~70% of CRC-related deaths could be prevented through improved screening

Sources: American Cancer Society, cancer.net

Lack of convenience and aversion to colonoscopy drives low screening compliance

COLONOSCOPY LIMITATIONS

BOWEL PREP

SEDATION

DISCOMFORT

CANCER SCREENING COMPLIANCE RATES



44M
Unscreened average risk individuals age 45-85

Sources: American Cancer Society National Colorectal Cancer Roundtable, National Cancer Institute, JAMA Network, Geneoscopy estimates

Noninvasive screening tests have seen rapid growth, but opportunities remain for further market expansion

cologuard® by EXACT SCIENCES

ANNUAL SALES AND VOLUME

Sources: SEC filings, Geneoscopy estimates

10%
Cologuard
Market share

Geneoscopy large growth opportunity

Introducing ColoSense™ – Geneoscopy's first commercial test

COLOSENSE
LIKE NO OTHER

Best-in-class performance
Highest sensitivity of a noninvasive CRC screening test from a prospective registrational clinical study

De-risked path to launch
On track for FDA-approval and CMS coverage in 1H 2024, ahead of launch in 3Q 2024

Commercial partner for scale
Multi-year Labcorp agreement will provide extensive patient and provider access at launch

RNA approach best addresses CRC screening in younger individuals

RNA sensitivity is consistent, while DNA sensitivity improves with age



CRC screening has become increasingly important for younger individuals

- Lowering the screening age added over 20 million individuals to the average risk screening population
- More than 40% of the screening-eligible population are individuals under the age of 50
- Individuals under the age of 55 are ~60% more likely to be diagnosed with late-stage disease
- Since 1994, CRC incidence among individuals under the age of 50 has increased by 51%

Sources: JNCI, American Cancer Society, FDA, Cancer Prevention Research, ColoSense (Barnell et. al, JAMA, 2023), Cologuard (P130017 SSED), Cologuard+ (Imperiale et. al, NEJM, 2024)
Note: Head-to-head study not completed. Clinical data are from independent, peer-reviewed studies

JAMA publication highlights strong clinical performance

Representative study cohort testing the full range of average-risk screening population (45 – 85 years)

Robust sensitivity for **CRC (94%) and AA (46%)** the highest reported in a registrational study

RNA preserves high sensitivity for **CRC (100%) and AA (45%)** in 45 to 49 age group



Original Investigation

October 23, 2023

ONLINE FIRST FREE

Multitarget Stool RNA Test for Colorectal Cancer Screening

Key Points

Question What is the performance of the novel multitarget stool RNA (mt-sRNA) test (ColoSense) for individuals 45 years and older undergoing colorectal cancer screening?

Findings A pivotal prospective, cross-sectional clinical trial comprising 8920 eligible participants was used to evaluate the sensitivity and specificity of the mt-sRNA test compared with

Design, Setting, and Participants The phase 3 clinical trial (COLOPREVENT) was a blinded, prospective, cross-sectional study to support a premarket approval application for a class III medical device. A total of 8920 participants were identified online using social media platforms and enrolled from June 2021 to June 2022 using a decentralized nurse call center. All participants completed the mt-sRNA test, which incorporated a commercially available fecal immunochemical test (FIT), concentration of 8 RNA transcripts, and participant-reported smoking status. Stool samples were collected prior to participants completing a colonoscopy at their local endoscopy center. The mt-sRNA test results (positive or negative) were compared with index lesions observed on colonoscopy. Over the course of 12 months, individuals 45 years and older were enrolled in the clinical trial using the decentralized recruitment strategy. Participants were enrolled

ColoSense™ will be the most sensitive non-invasive CRC screening test



CRC sensitivity ranks as the #1 factor in determining a preferred CRC screening approach

AA sensitivity ranks as the #2 factor in determining a preferred CRC screening approach

Sources: ColoSense (Barnell et. al, JAMA, 2023), Cologuard+/FIT (Imperiale et. al, NEJM, 2024), Shield (Chung et. al, NEJM, 2024), Internal Market Research

De-risked pathway for FDA approval and CMS coverage ahead of commercial launch in 1H2024

JAMA Publication — Oct 2023

FDA Approval — 2Q 2024

CMS Coverage — 2Q 2024

©2024 GENEOSCOPY, INC.


Geneoscopy has a rapid path to broad market access
Covered Lives
110M
95M
85M
74M
61M
American Cancer Society
Guideline Inclusion
U.S. Preventive Services Task Force
Guideline Inclusion
CMS
NCD Inclusion
NCQA
Guideline Inclusion
COLOSENSE
Product Launch
JAMA
Publication
FDA
Approval
2023
2024
2025
2026
85M lives
covered in first year of launch
17 | PROPRIETARY AND CONFIDENTIAL
©2024 GENEOSCOPY, INC.


Labcorp collaboration provides infrastructure for efficient growth...
geneoscopy
Transforming Gastrointestinal Health
+
labcorp
Rapid
market access
Scale
of distribution
Clinical workflow
integration
18 | PROPRIETARY AND CONFIDENTIAL

...through extensive patient and provider access

>90%
US lives contracted in-network

1,000+
primary care sales representatives

Leading
national provider of FIT screening

>90%
orders received electronically

160M+
annual patient interactions

600M+
tests performed annually

4,000+
hospital system integrations

45B+
lab results in proprietary data sets

labcorp **OUR MISSION:** Improve health, improve lives

Key growth drivers for ColoSense

1. Superior sensitivity, with significant differentiation in the 45–49 age group, driven by RNA approach
2. Integration into Labcorp's best-in-class infrastructure for laboratory test adoption and a seamless patient/provider experience
3. Continued growth of overall market and further penetration of non-invasive screening tests



©2014 GENISCOPY, INC.

Inflammatory bowel disease presents significant unmet needs

3M
Individuals living with IBD

$3B
IBD diagnostics market

- Growing incidence and testing opportunity with 125K new diagnoses annually
- Chronic condition with high patient and systemic burden
- Emerging market with significant white space and limited competition

Sources: Census data, Geneoscopy estimates (includes US markets only)

Lack of noninvasive testing solutions creates opportunity

Fecal calprotectin (stool-protein) and c-reactive protein (blood-protein) are the most commonly-used inflammatory markers, but lack the accuracy for clinicians to improve the current standard of care

DIAGNOSIS
>50% of patients are misdiagnosed before receiving an IBD diagnosis

PROGNOSIS
No validated methods to predict flares or identify patients with high-risk phenotypes (e.g., stricturing)

THERAPEUTIC SELECTION
No validated methods for precision medicine or data-driven approaches to dictate treatment

PATIENT MONITORING
Colonoscopy and patient surveys are the primary methods for assessing disease activity

©2024 GENEDSCOPY, INC.

Our technology is already addressing these critical unmet needs…

Extensive Pharma Activity

Anti-IL 12/23 Agents
Stelara, Skyrizi, omvoh, Tremfya

JAK Inhibitors
RINVOQ, XELJANZ, Jyseleca

Anti-TNF Agents
HUMIRA, Remicade, CIMZIA, Simponi

Anti-Integrin Inhibitor
Entyvio

S1P1 Modulator
ZEPOSIA

35+ Additional Drugs in Phase I-III Development

Geneoscopy Advantage

THERAPEUTIC SELECTION
seRNA signature used to identify and enrich treatment population for likely responders

PATIENT MONITORING
seRNA signature used to noninvasively measure mucosal healing and impact of treatment

...with numerous brand-name partnerships already showing promise and others expected to launch in 2024

	Takeda	ADISO THERAPEUTICS	teva	Takeda	Bristol Myers Squibb
Target of Intent/MOA	TYK2	MRP2/FPR1	TL1A	α4β7 Integrin	Undisclosed

	AstraZeneca	abbvie	GILEAD	Johnson&Johnson	Northwestern University
Target of Intent/MOA	Undisclosed	Undisclosed	Undisclosed	Undisclosed	Hyperbaric Oxygen

Geneoscopy is building the most expansive IBD database that will drive product development for companion diagnostics (CDx) and in-vitro diagnostics (IVD)

Note: This slide is a representative example and does not make warrants or representation to these companies and targets

©2023 GENEOSCOPY, INC.

Vision to become the leader in GI health diagnostics

CRC	IBD	Other Unmet Needs
ColoSense™ 2.0 2nd generation CRC screening test with enhanced sensitivity profile	**Precision Medicine** Clinical assays to assist with therapy selection **Disease Management** Clinical assays to monitor patients noninvasively	**Lynch Syndrome / FAP** **Celiac Disease** **Irritable Bowel Syndrome**

Geneoscopy is Transforming Gastrointestinal Health

©2024 GENEOSCOPY, INC.

Geneoscopy possesses extensive experience developing and commercializing transformational diagnostics products

LEADERSHIP TEAM

- **Andrew Barnell, MBA** — Chief Executive Officer
- **Erica Barnell, MD/PhD** — Chief Medical / Science Officer
- **Matt Sargent** — Chief Commercial Officer
- **Julie LaRocca, MS** — SVP, Quality / Regulatory
- **Jim Fitzgibbon, MBA** — VP, Bus Dev / BioPharma Partnering
- **Ryan Gorman** — VP, Sales
- **Gary Gallimore** — SVP, Software / IT
- **Jeff Salzman, MHM** — VP, Market Access
- **Tyler Aldredge** — VP, Operations

ADVISORS

- **Don Hardison** — Board of Directors Chairman
- **David Lieberman, MD/AGAF** — CRC Advisory Board Chairman
- **Matt Ciorba, MD** — IBD Advisory Board Chairman

EXPERIENCE

Roche Diagnostics, Quest Diagnostics, labcorp, GUARDANT, Genomic Health, FOUNDATION MEDICINE, HOLOGIC, EXACT SCIENCES, CARIS, BIOTHERANOSTICS, Washington University in St. Louis School of Medicine, CareDx, Interpace Biosciences, McDonnell Genome Institute, Harbinger Health, J.P.Morgan, AstraZeneca, GoodStart Genetics, STRATA

KEY INVESTORS

Cultivation Capital, LIGHTCHAIN CAPITAL, labcorp, MORNINGSIDE, NT Syndicate